The Peptide Field
Menu

18 FDA label and trial tables · Checked

Nausea vs placebo, out of 100 people

Zepbound label

Placebo8%
On Zepbound (by dose)25% to 29%

In the Zepbound label, 25% to 29% on Zepbound (by dose) had nausea. On placebo, 8% did.

See all 18 tablesFrom the label: more on nausea

Every table that lists nausea

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

FDA-approved medicines

ForteoFDA-approved product

Women and men with osteoporosis

Row in the source: Nausea

Placebo6.7%
On Forteo8.5%
Who was studied
1,382 adults aged 28 to 86. 691 got Forteo and 691 got placebo. Everyone also took calcium and vitamin D. The middle trial length was 11 months for men and 19 months for women.
How long
11 months (men), 19 months (women)
Source
Forteo prescribing information on DailyMed . FDA label revised August 2026.

MounjaroFDA-approved product

Mounjaro trials in adults with type 2 diabetes

Row in the source: Nausea

Placebo4%
On Mounjaro (by dose)12% to 18%
Who was studied
Adults with type 2 diabetes in 2 trials. One tested Mounjaro alone. The other added it to long-acting insulin, with or without metformin. 718 adults took Mounjaro in three dose groups and 235 took placebo.
How long
40 weeks
Source
Mounjaro prescribing information on DailyMed . FDA label revised August 2026.

OzempicFDA-approved product

Ozempic trials in adults with type 2 diabetes

Row in the source: Nausea

Placebo6.1%
On Ozempic (by dose)15.8% to 20.3%
Who was studied
Adults with type 2 diabetes in 2 trials. One tested Ozempic alone. The other added it to long-acting insulin. 521 adults took Ozempic in two dose groups and 262 took placebo.
How long
30 weeks
Source
Ozempic prescribing information on DailyMed . FDA label revised June 2026.

SaxendaFDA-approved product

Saxenda trials in adults with obesity or overweight

Row in the source: Nausea

Placebo13.8%
On Saxenda39.3%
Who was studied
Adults with obesity or overweight in 5 trials. 3,384 got Saxenda and 1,941 got placebo. 15% had type 2 diabetes. Everyone also got advice on diet and exercise.
How long
32 to 56 weeks, some up to about 3 years
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

SaxendaFDA-approved product

Saxenda trial in teens with obesity

Row in the source: Nausea

Placebo14.3%
On Saxenda42.4%
Who was studied
Children aged 12 and older with obesity. None had type 2 diabetes. 125 got Saxenda and 126 got placebo.
How long
56 weeks
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

TymlosFDA-approved product

Women after menopause with osteoporosis

Row in the source: Nausea

Placebo3%
On Tymlos8%
Who was studied
Women aged 49 to 86. The label counts 822 women on Tymlos and 820 on placebo.
How long
18 months
Source
Tymlos prescribing information on DailyMed . FDA label revised August 2026.

TymlosFDA-approved product

Men with osteoporosis

Row in the source: Nausea

Placebo0%
On Tymlos3%
Who was studied
Men aged 42 to 85. 149 men got Tymlos and 79 got placebo.
How long
12 months
Source
Tymlos prescribing information on DailyMed . FDA label revised August 2026.

VictozaFDA-approved product

Victoza trials in adults with type 2 diabetes

Row in the source: Nausea

Placebo5%
On Victoza (by dose)18% to 20%
Who was studied
Adults with type 2 diabetes in 5 trials. The table counts 1,669 adults on Victoza in two dose groups and 661 on placebo.
How long
At least 26 weeks each
Source
Victoza prescribing information on DailyMed . FDA label revised October 2025.

VyleesiFDA-approved product

Premenopausal women with HSDD

Row in the source: Nausea

Placebo1.3%
On Vyleesi40.0%
Who was studied
1,247 women aged 19 to 56 in two matching trials. 627 got Vyleesi and 620 got placebo.
How long
24 weeks
Source
Vyleesi prescribing information on DailyMed . FDA label revised March 2024.

WegovyFDA-approved product

Wegovy trials in adults with obesity or overweight

Row in the source: Nausea

Placebo16%
On Wegovy44%
Who was studied
Adults with obesity or overweight in 3 trials. 2,116 got Wegovy and 1,261 got placebo. 19% had type 2 diabetes.
How long
Up to 68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

WegovyFDA-approved product

Wegovy trial in teens with obesity

Row in the source: Nausea

Placebo18%
On Wegovy42%
Who was studied
Children aged 12 and older with obesity. 133 got Wegovy and 67 got placebo.
How long
68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

ZepboundFDA-approved product

Zepbound trials in adults with obesity or overweight

Row in the source: Nausea

Placebo8%
On Zepbound (by dose)25% to 29%
Who was studied
Adults with obesity or overweight in 2 trials. One trial included only people with type 2 diabetes; the other left them out. 2,519 got Zepbound in three dose groups and 958 got placebo.
How long
Up to 72 weeks
Source
Zepbound prescribing information on DailyMed . FDA label revised August 2026.

Medicines that are not FDA-approved

CagrilintideNo FDA-approved product

Phase 2 weight trial (NCT03856047)

Row in the source: Nausea

Placebo17.8%
On cagrilintide (by dose)19.8% to 46.5%
Who was studied
706 adults without diabetes who had obesity, or overweight with high blood pressure or unhealthy blood-fat levels. 506 got cagrilintide and 101 got placebo. A liraglutide group of 99 is not shown.
How long
26 weeks of treatment, side effects counted to week 32
Source
ClinicalTrials.gov posted results . Trial registry results posted July 18, 2023.

RetatrutideNo FDA-approved product

TRIUMPH-1

Row in the source: Nausea

Placebo14.8%
On retatrutide (by dose)28.6% to 42.4%
Who was studied
Adults without diabetes who had obesity, or overweight and at least one health problem linked to weight.
How long
80 weeks
Source
Lilly early results . Company trial results posted May 21, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-2

Row in the source: Nausea

Placebo8.0%
On retatrutide (by dose)13.7% to 28.0%
Who was studied
Adults with type 2 diabetes and obesity or overweight.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-3

Row in the source: Nausea

Placebo5.8%
On retatrutide (by dose)21.7% to 22.4%
Who was studied
Adults with severe obesity and heart or blood vessel disease, with or without type 2 diabetes.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

Phase 2 obesity trial (NCT04881760)

Row in the source: Nausea

Placebo11.4%
On retatrutide (by dose)14.5% to 60.0%
Who was studied
338 adults with obesity, or with overweight and a health problem linked to weight.
How long
48 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted September 13, 2023.

RetatrutideNo FDA-approved product

Phase 2 type 2 diabetes trial (NCT04867785)

Row in the source: Nausea

Placebo4.4%
On retatrutide (by dose)4.3% to 41.7%
Who was studied
281 adults with type 2 diabetes. This trial also had a dulaglutide group, which is not shown.
How long
36 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted July 3, 2023.

More from the labels

These lines are copied from our side effect pages, word for word.

Vyleesi: Nausea

Nausea usually started within an hour and lasted about two hours. It was most common after the first dose, when 21% of women had it. After later doses, about 3% did. 13% of women on Vyleesi took medicine for nausea.

From Vyleesi prescribing information on DailyMed .

Saxenda: Stomach and bowel problems

In the Saxenda trials in adults, 68% of people on Saxenda and 39% on placebo had a stomach or bowel problem. Most were mild or moderate. Nausea became less common the longer people stayed on the medicine.

From Saxenda prescribing information on DailyMed .

Mounjaro and Zepbound: Stomach and bowel problems

Both labels say most nausea, vomiting, and diarrhea happened while the dose was being raised and became less common over time.

From Mounjaro prescribing information on DailyMed  and Zepbound prescribing information on DailyMed .

Higher-dose Wegovy (Wegovy HD)

Wegovy HD is a higher weekly dose. Two 72-week trials compared it with the usual Wegovy dose and with placebo. Nausea was reported by 39% on Wegovy HD, 35% on the usual dose, and 13% on placebo.

Changes in skin feeling, such as tingling, burning, or sensitive skin, were reported by 22%, 6%, and under 1%. Among people on Wegovy HD who had these skin changes, 18% did not report recovering during the trial. Hair loss was reported by 6%, 3%, and 1%.

From Wegovy prescribing information on DailyMed .

How long were people watched?

Each bar is one set of trials. The dots on this page come only from the time inside each bar.

Stated length Range in the source Some people only No end date given

  1. Forteo, adults with osteoporosis11 months (men), 19 months (women)

  2. Mounjaro, adults with type 2 diabetes40 weeks

  3. Ozempic, adults with type 2 diabetes30 weeks

  4. Saxenda, adults32 to 56 weeks, some up to about 3 years

  5. Saxenda, teens56 weeks

  6. Tymlos, women18 months

  7. Tymlos, men12 months

  8. Victoza, adults with type 2 diabetesAt least 26 weeks each

  9. Vyleesi, women24 weeks

  10. Wegovy, adultsUp to 68 weeks

  11. Wegovy, teens68 weeks

  12. Zepbound, adultsUp to 72 weeks

  13. Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32

  14. Retatrutide, TRIUMPH-180 weeks

  15. Retatrutide, TRIUMPH-280 weeks

  16. Retatrutide, TRIUMPH-380 weeks

  17. Retatrutide, phase 2 (obesity)48 weeks

  18. Retatrutide, phase 2 (diabetes)36 weeks

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?